Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Table 4 Correlation between HRQoL symptoms and selected adverse events

Symptom/Scale	Study 206 (N = 56)		Study 208 (N = 52)
Symptom/Scale	Spearman Correlation Coefficient (95% CI)	P Value	Spearman Correlation Coefficient (95% CI)	P Value
QLQ-C30
Fatigue	0.14 (−0.13, 0.39)	0.3059	0.31 (0.03, 0.53)	0.0260
Nausea and vomiting	0.33 (0.07, 0.55)	0.0117	0.50 (0.26, 0.68)	0.0001
Pain	0.13 (−0.14, 0.37)	0.3586	0.41 (0.15, 0.61)	0.0025
Dyspnea	0.31 (0.05, 0.53)	0.0201	0.49 (0.25, 0.67)	0.0002
Insomnia	0.24 (−0.03, 0.47)	0.0809	0.35 (0.08, 0.57)	0.0104
Appetite loss	0.35 (0.09, 0.56)	0.0080	0.23 (−0.05, 0.47)	0.1055
Constipation	0.31 (0.05, 0.53)	0.0191	0.30 (0.03, 0.53)	0.0283
Diarrhea	0.54 (0.32, 0.70)	< 0.0001	0.40 (0.14, 0.60)	0.0032
QLQ-BR23
Upset by hair loss^a	0.16 (−0.11, 0.41)	0.2345	0.04 (−0.24, 0.31)	0.8026

CI confidence interval, HRQoL health-related quality of life, QLQ-C30 Quality-of-Life Questionnaire for Patients with Cancer, QLQ-BR23 Quality-of-Life Questionnaire for Breast Cancer
^an ≤ 10 at each visit

ISSN: 1471-2407